Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 3Primary Myelofibrosis 1Pancreatic Neoplasms 1Leukemia 1Hematologic Diseases 1Colorectal Neoplasms 1Bone Marrow Diseases 1

Interventions

ruxolitinib 28navitoclax 6Azacitidine 511-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 4parsaclisib 3luspatercept 3itacitinib 3givinostat hydrochloride 3givinostat 3fedratinib 3INCB039110 3selinexor 2pomalidomide 2imetelstat 2bomedemstat 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2LY2784544 2INCB057643 2GRN163L peptide 2venetoclax 1triciribine 1tagraxofusp 1spartalizumab 1sonidegib 1simtuzumab 1sabatolimab 1rucaparib 1ridaforolimus 1quizartinib 1pelcitoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Primary Myelofibrosis × simtuzumab × Clear all
NCT01369498 2020-07-01

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Gilead Sciences

Phase 2 Completed
54 enrolled 16 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡